MA48751B1 - Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax - Google Patents

Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Info

Publication number
MA48751B1
MA48751B1 MA48751A MA48751A MA48751B1 MA 48751 B1 MA48751 B1 MA 48751B1 MA 48751 A MA48751 A MA 48751A MA 48751 A MA48751 A MA 48751A MA 48751 B1 MA48751 B1 MA 48751B1
Authority
MA
Morocco
Prior art keywords
treatment
venetoclax
lymphoma
paradigm
antibody
Prior art date
Application number
MA48751A
Other languages
English (en)
Other versions
MA48751A (fr
Inventor
Mark Winderlich
Peter Kelemen
Michael Schwarz
Steffen Heeger
Dominika Weinelt
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA48751A publication Critical patent/MA48751A/fr
Publication of MA48751B1 publication Critical patent/MA48751B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps anti-cd19 et venetoclax destinés à être utilisés dans le traitement d'un lymphome non hodgkinien, d'une leucémie lymphoïde chronique et/ou d'un lymphome à petits lymphocytes. Les anticorps anti-cd19, en particulier mor00208, et le venetoclax sont administrés à des patients souffrant d'un lymphome non hodgkinien (lnh), d'une leucémie lymphocytaire chronique (llc) et/ou d'un lymphome à petits lymphocytes (lpl) selon un paradigme de traitement spécifique pour atténuer le syndrome de lyse tumorale associé à la thérapie.
MA48751A 2017-05-31 2018-05-30 Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax MA48751B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173712 2017-05-31
PCT/EP2018/064229 WO2018220040A1 (fr) 2017-05-31 2018-05-30 Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax

Publications (2)

Publication Number Publication Date
MA48751A MA48751A (fr) 2020-04-08
MA48751B1 true MA48751B1 (fr) 2023-11-30

Family

ID=59070416

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48751A MA48751B1 (fr) 2017-05-31 2018-05-30 Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Country Status (27)

Country Link
US (1) US20250186460A1 (fr)
EP (2) EP3630177B1 (fr)
JP (2) JP7399713B2 (fr)
KR (2) KR20240117655A (fr)
CN (1) CN110678201A (fr)
AU (2) AU2018276384B2 (fr)
BR (1) BR112019025034A2 (fr)
CA (1) CA3062400A1 (fr)
CY (1) CY1126559T1 (fr)
DK (1) DK3630177T5 (fr)
ES (1) ES2961940T3 (fr)
FI (1) FI3630177T3 (fr)
HR (1) HRP20231229T1 (fr)
HU (1) HUE063119T2 (fr)
IL (2) IL297461B2 (fr)
LT (1) LT3630177T (fr)
MA (1) MA48751B1 (fr)
MD (1) MD3630177T2 (fr)
MX (2) MX2019014330A (fr)
PL (1) PL3630177T3 (fr)
PT (1) PT3630177T (fr)
RS (1) RS64746B1 (fr)
SG (1) SG11201909715VA (fr)
SI (1) SI3630177T1 (fr)
SM (1) SMT202300338T1 (fr)
WO (1) WO2018220040A1 (fr)
ZA (1) ZA201907369B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) * 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2022115120A1 (fr) * 2020-11-30 2022-06-02 Incyte Corporation Polythérapie comprenant un anticorps anti-cd19 et le parsaclisib
EP4251138A1 (fr) * 2020-11-30 2023-10-04 Incyte Corporation Polythérapie faisant appel à un anticorps anti-cd19 et à du parsaclisib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534639C (fr) 2003-07-31 2013-07-30 Immunomedics, Inc. Anticorps anti-cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2611814A1 (fr) 2005-06-20 2007-01-04 Medarex, Inc. Anticorps cd19 et utilisations
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20140064873A (ko) 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
HRP20220224T1 (hr) 2011-08-16 2022-04-29 Morphosys Ag Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) * 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof

Also Published As

Publication number Publication date
RU2019139552A (ru) 2021-07-01
IL297461B1 (en) 2024-05-01
SG11201909715VA (en) 2019-11-28
IL270855B (en) 2022-11-01
MX2023013228A (es) 2024-04-16
US20250186460A1 (en) 2025-06-12
AU2018276384A1 (en) 2019-11-07
RU2019139552A3 (fr) 2021-09-22
SI3630177T1 (sl) 2023-12-29
FI3630177T3 (fi) 2023-10-18
MD3630177T2 (ro) 2024-01-31
AU2018276384B2 (en) 2025-02-13
MA48751A (fr) 2020-04-08
IL270855B2 (en) 2023-03-01
WO2018220040A1 (fr) 2018-12-06
MX2019014330A (es) 2020-02-05
KR20240117655A (ko) 2024-08-01
BR112019025034A2 (pt) 2020-06-30
HRP20231229T1 (hr) 2024-02-02
PL3630177T3 (pl) 2024-04-08
CN110678201A (zh) 2020-01-10
AU2025203436A1 (en) 2025-06-05
HUE063119T2 (hu) 2024-01-28
EP3630177B1 (fr) 2023-08-09
DK3630177T5 (da) 2024-09-02
DK3630177T3 (da) 2023-10-16
LT3630177T (lt) 2023-10-25
JP2020521777A (ja) 2020-07-27
SMT202300338T1 (it) 2023-11-13
ES2961940T3 (es) 2024-03-14
RS64746B1 (sr) 2023-11-30
EP3630177A1 (fr) 2020-04-08
EP4268900A3 (fr) 2024-03-06
CA3062400A1 (fr) 2018-12-06
KR20200010472A (ko) 2020-01-30
JP7399713B2 (ja) 2023-12-18
PT3630177T (pt) 2023-11-10
IL297461B2 (en) 2024-09-01
EP4268900A2 (fr) 2023-11-01
IL297461A (en) 2022-12-01
JP2024028865A (ja) 2024-03-05
CY1126559T1 (el) 2026-02-25
IL270855A (en) 2020-01-30
ZA201907369B (en) 2024-04-24

Similar Documents

Publication Publication Date Title
MA48751B1 (fr) Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax
MA52773B1 (fr) Anticorps anti-cd3 et leurs utilisations
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
MA43794B1 (fr) Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA44146B1 (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
MA43075A1 (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA42020A1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA53069B1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA42021A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
MA34753B1 (fr) Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MA40621B1 (fr) Traitement de la fibrodysplasie ossifiante progressive
MA38478A1 (fr) Anticorps anti-pac1 humains
MA43773B1 (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
MA43477A1 (fr) Immunothérapie contre le mélanome et d'autres cancers
MA54975B1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA42440B1 (fr) Anticorps contre la sortilin qui inhibent la liason à la progranulin
MA38161A1 (fr) Anticorps anti-bmp-6